Prothena is stopping the development of AL amyloidosis treatment NEOD001 following unfavorable results in the phase 2b Pronto study. The Phase 2b Pronto study did not meet its primary or secondary endpoints. A phase 3 […]
French biotech Adocia has announced the initiation of a Phase I study of BioChaperone Pramlintide Insulin, a treatment that could better regulate glucose levels in type 1 diabetes patients. The product is made up of […]
A phase 3 study of Incyte’s epacadostat in combination with Merck’s Keytruda (pembrolizumab) in patients with unresectable or metastatic melanoma has failed meet to primary endpoint. The external data monitoring committee (eDMC) concluded that the […]
Eli Lilly’ liver cancer treatment Cyramza (ramucirumab) has met its primary endpoint of overall survival (OS) and the secondary endpoint of progression-free survival (PFS) in the phase 3 Reach-2 study. The company has revealed the […]
Pfizer has announced positive results from its Phase III study of experimental drug tafamidis in patients with transthyretin cardiomyopathy. According to topline results, the drug met its primary endpoint, demonstrating a statistically-significant reduction in the […]